Adolor rated outperform by RBC

Adolor Corp. was reiterated at outperform, above average risk by RBC Capital Markets analyst Michael J. Yee on the expectation that alvimopan will be approved by the PDUFA date of Nov. 9. The approval is supported by the totality of phase 3 data, including the recent positive Study 314 data, according to the analyst. Shares of the Exton, Pa.-based biopharmaceutical company were down 12 cents, or 0.87%, at $13.71. (Nasdaq: ADLR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.